A new cancer-associated antigen CA130, recognised by two monoclonal antibodies (moABs) 130-22 and 145-9, was often found to be present at high levels in the sera of patients with ovarian cancer. There was a strong correlation between CA130 and CA125 values. The epitopes recognised by moABs 130-22 and 145-9 were proved to differ from the CA125 epitope, but to exist on the molecule bearing CA125. Unlike OC125, the majority of 130-22/145-9 activity was associated with a much lower molecular mass (less than 200 kDa), indicating that a lower molecular mass immunoreactive determination may be a unique CA130 antigenic determinant within CA125 molecule. Clinical data demonstrate that, (1) elevated levels of CA130 determinant were found in the sera of 91.3% of women with epithelial ovarian cancer, (2) falling or rising levels of CA130 correlated with regression or progression of ovarian cancer in >95% of cases, (3) normalisation of serum CA130 levels at response does not imply no microscopic residual disease, but CA130 changes during follow-up support the evaluation of recurrence and can be used as a monitoring marker in an individual patient.
Monoclonal antibodies (moAbs) that recognise the carbohydrate structures of cell-surface glycoproteins and glycolipids of cancer cells have been regarded as useful tools for characterising cell types and for cancer diagnosis through assaying of antigenic glycoconjugates secreted into the bloodstream and as assessed from immunohistochemical studies (Herlyn et al., 1982; Springer, 1984) . Cell surface glycoconjugates, the composition of which has been shown to change during tumorigenesis, participate in a biological function (Hakomori, 1985; Springer et al., 1986; Itzkowitz et al., 1989) . The quantitative and qualitative changes in glycoconjugates on cancer cell surfaces are still under investigation (Itzkowitz et al., 1990; Kobayashi et al., 1991) .
The murine moAB OC125 recognises the antigen CA125, expressed in over 80% of nonmucinous human ovarian cancers (Bast et al., 1981; Bast et al., 1983; Niloff et al., 1984; Klug et al., 1984; Kuzuya et al., 1986; Zanaboni et al., 1987) . CA125 has by far been the most useful antigen for detecting and following-up patients with ovarian cancer (Bast et al., 1983; Canney et al., 1984; Schilthuis et al., 1987; Vergote et al., 1987) . However, the weak point of this antigen is its relatively low frequency in mucinous-type ovarian cancers and its high false-positive rate especially in patients with endometriosis (Pittaway & Feyez, 1986) .
New moAB 130-22 recognising a glycoprotein have been made by Matsuoka et al. (1987) . CA130 is a glycoprotein recognised by moABs, 130-22 and 145-9 , produced by immunisation with human lung adenocarcinoma cell line PC-9. The correlation coefficient between the serum levels of CA130 and CA125 in patients with lung cancer was reported to be 0.8034 (Matsubara et al., 1989) . Also, serum CA130 levels in gynaecologic disease were closely correlated with serum CA125 levels, demonstrating quite a high correlation coefficient (r = 0.965) (Inaba et al., 1989) . (Imai et al., 1989; Imai et al., 1990) . Another cell line, designated as HOC-I, was established from a recurrent region of ovarian endometrioid carcinoma (Fujii, 1989 (Davis et al., 1986) . In brief, pooled CM were filtered and concentrated in an Amicon filter apparatus with a molecular mass cutoff of 30 kDa (Centricon-30). The concentrated CM was subjected to perchloric acid precipitation (0.6 M), then the acid-soluble fraction was neutralised (IN NaOH) and dialysed against water. This sample was applied on a Sephacryl S-300 column, as described previusly (Matsuoka et al., 1987) . The fraction containing CA125 activity (void volume) were pooled, dialysed and then concentrated. The sample was treated with urea (6 M, 30 min, 45°C) to disaggregate the high-molecular-mass CA125 molecule, and further fractionation was accomplished by subsequent chromatography on a Sepharose 6B column equilibrated in 50 mM Tris, 6 M urea, 0.1% SDS (pH 8.0 to HOC-I cell extracts were determined by measuring their ability to inhibit the bindings of moAB by different sources of CA125 antigens. Endometriotic cyst fluid, menstrual blood, amniotic fluid, meconium supernatant (as a negative control), CM from SHIN-3 and HOC-I (crude CA125 antigen), CA125 antigen purified from CM of HOC-I, CA125 > 200 kDa, and CA 125 <200 kDa were used as competitors. To determine if CA125 antigens are involved in the reactivity to moABs, the inhibitory activities of these antigens were assayed. After preincubation of competitors and each moAB (1 h, 23°C), the reaction mixture was transferred to microtiter plates coated with HOC-I cell extracts (1 h, 23°C). Thereafter, the procedure was as described above. 1.3 ig ml ' of each moAB was used for inhibition assays.
In addition, 96 well microtiter plates coated with 1.0 Lg ml-' immobilised antibody (OC 125 or 130-22) were incubated with undiluted serum of patient with ovarian cancer (serum CA125 level= 650 U ml-', 100p1d, 3 h, 23°C).
After five washes, horseradish peroxidase (HRP)-labeled antibody (HRP-OC125 or HRP-145-9) was incubated together with OC125, 130-22, or 145-9 (0-8pjgml-'), respectively, as a competitor (3 h, 23°C). The enzyme reaction was performed.
Patient characteristics and serum samples Serum samples that had been randomly drawn from 126 patients with epithelial ovarian cancer during the period 1985 through 1991 and from 397 women who were healthy, or possessed benign gynaecologic diseases were obtained from a bank of sera preserved at the Department of Gynaecology, Hamamatsu University School of Medicine, Shizuoka, Japan (Table I ). Blood collection was performed within protocols approved by the members of the Gynaecological Cancer Committee of this institute. All patients diagnosed at the Department of Gynaecology, Hamamatsu University hospital and its related hospitals entered the study. The tumour response was assessed from the computerised tomographic (CT) scan, ultrasonographic (US) examination and routine clinical examinations, with measurement of the product of the largest diameter and the diameter perpendicular to it. Registration of disease progression requires a 25% or more increase in the size of the existing lesions or the appearance of clinically measurable new lesions. Disease regression requires at least a 50% decrease in size for at least 4 weeks for partial response and a disappearance of all clinical signs of malignancy for complete response (Vergote et al., 1987) . Patients who died while on study, yet without known progressive disease as defined, were considered to have progression at the date of death.
Determination of serum CA 130 and CA 125
Circulating serum CA130 antigen was assayed in sera by means of a double-determinant sandwich immunoradiometric assay system developed by using two moABs, 130-22 and 145-9 (Matsuoka, 1988) . Serum samples were analysed in duplicate. The intra-assay and inter-assay coefficients of variation did not exceed 7.0%. Based on the previous study (Matsuoka et al., 1987; Inaba et al., 1989) , an CA130 antigen level > 35 U ml-' was defined as elevated.
Serum CA125 assays were performed in duplicate using kits provided by Centocor, Inc (Malvern, PA). A CA125 level of > 35 U ml-' was defined as elevated.
The nonparametric Wilcoxon test was used for calculations of statistical significance.
Results
Characterisation of antigenic determinant of CA130 antigen To investigate the reactivity of each moAB (OC125, 130-22, or 145-9) with ovarian cancer cell extracts, a microtiter plate coated with supernatants of sonicated SHIN-3 or HOC-I cells was incubated with different concentrations (0-8.0 jig ml-') of moABs as described in Figure la of endometriotic cyst fluid, menstrual blood, amniotic fluid, CM from SHIN-3 and HOC-I, and purified CA125 antigen inhibiting the binding of 130-22 or 145-9 were closely related to that of OC125 (Figure 3 ). Meconium solution did not react with these moABs. CA125 <200 kDa had a significant inhibitory activity toward the reaction between cancer cell extracts and antibodies (Kivinen et al., 1986; Shilthuis et al., 1987) . We assayed these two antigen levels in sera from patients with benign gynaecologic disease. CA130 and CA125 was positive in 36.2% and 37.1% of patients with benign disease and in 60.6% and 62.0% of those with endometriosis, respectively. Like CA125, CA130 also showed a high false-positive rate in endometriosis in particular. Our data indicated that serum CA130 levels were closely correlated with serum CA125 levels, demonstrating quite a high correlation coefficient (r = 0.914). CA130 and CA125 were similar in terms of sensitivity (91.3% vs 90.5%) and specificity (75.1% vs 74.5%). Serum CA130 and CA125 levels were assayed simultaneously in 119 patients with residual tumour of 2cm or less after primary cytoreductive surgery. Results of treatment at SLO are described in Table II . The difference between the CA130 and CA125 levels in pathological complete responders and in surgical complete responders was not significant. In contrast, the differences between these levels in pathological complete responders and in partial responders were significant (P <0.05). Four (10.3%) of 39 patients without residual disease exceeded 35 U ml-' at SLO. For these patients recurrences have not been confirmed for at least 2 years. Six (18.8%) of 32 surgical complete responders, 14 (46.7%) of 30 partial responders, and all of 18 patients with progressive disease showed serum CA130 levels ) 35 U ml-'.
Thirty-eight (47.5%) of 80 patients with residual disease showed levels of CA130 above the cutoff value. Namely, the sensitivity of CA130 in serum at SLO was 47.5% (38/80) yielded essentially identical results in detecting patients with disease at the time of the SLO. We next examined the time when the increase in serum CA130 levels occurs during follow-up (Table III) . Sixty-four of 119 patients showed recurrence during follow-up. In 95.3% (61/64) of the patients the CA130 increase was correlated to tumour progression or recurrence.
In 40.6% (26/64) the increase occurred at recurrence, and in 4.7% (3/64) occurred after recurrence and before death. In 50.0% (32/64) there was an increase before recurrence. In three patients (4.7%; two patients with mucinous adenocarcinoma, stage II and one case with clear cell carcinoma, stage III) there were no increase in CA130 levels until death. In one patient with partial response at SLO and in two cases with progressive disease at SLO, a rise in serum CA130 levels predated rising serum CA125 levels. Statistical analysis showed that CA125 and CA130 were similar in terms of the sensitivity, the specificity, the positive and negative predictive value at SLO. Also, the simultaneous assay of CA125 showed that similar results were obtained in terms of the time when the increase in serum CA125 levels occurs during follow-up. A strong correlation was found between CA130 and CA125, suggesting that the use of both assays does not further increase the ability to detect microscopic disease at SLO or during follow-up, since they yielded essentially identical results.
Discussion
CA130 is a glycoprotein recognised by moABs 130-22 and 145-9. Using these moABs a sensitive sandwich immunoradiometric assay for CA130 was developed (Matsuoka, 1988) . CA130 is a new tumour marker, different from CA125, since it has been considered that moABs and OC125 recognise distinct antigenic determinants on the same antigen (Endo et al., 1988) . The antigenic determinant recog- nised by 130-22 or 145-9 contains a protein moiety because the reactivity was greatly diminished by trypsin. To clarify the epitopic structure of CA130, the reactivity of 130-22 or 145-9 with various kinds of CA125 antigens were investigated by a competitive inhibition assay, which revealed that the reactivity of Buller, R.E. et al. (1991) assumed that there is a relationship between the amount of residual tumour after cytoreductive surgery and serum CA125 levels, and the decline in serum CA125 levels in patients with effectively treated epithelial ovarian cancer follows an exponential regression. Further prospective clinical trial in a larger series should be carried out in order to investigate the clinical usefulness of CA130 as a follow-up marker in ovarian cancer, and to determine the threshold of the CA130 test distinguishing surgical complete responders from patients with residual disease.
